Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer by Francini, E. & Sweeney, C. J.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the author's
institution and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier's archiving and manuscript policies are
encouraged to visit:
http://www.elsevier.com/authorsrights
E U R O P E A N U R O L O G Y 7 0 ( 2 0 1 6 ) 4 1 0 – 4 1 2
avai lable at www.sciencedirect .com
journal homepage: www.europeanurology.com
Author's Personal CopyBrief Correspondence
Docetaxel Activity in the Era of Life-prolonging Hormonal
Therapies for Metastatic Castration-resistant Prostate CancerEdoardo Francini a [3_TD$DIFF],b,*, Christopher J. Sweeney b [4_TD$DIFF]
a Medical Oncology Unit, Policlinico Umberto I Hospital, University of Rome, Via del Policlinico 155, 00161 Roma, Italy; b Dana-Farber Cancer Institute, Lank
[5_TD$DIFF]Center for Genitourinary Oncology [6_TD$DIFF], 450 Brookline Avenue, Boston, MA[7_TD$DIFF] 02215, USAArticle info
Article history:









For >6 yr, docetaxel with prednisone was the only treatment with survival benefits for
metastatic castration-resistant prostate cancer (mCRPC). More recently, in clinical
practice, abiraterone acetate has been commonly administered prior to docetaxel for
the treatment of mCRPC. Our study aimed to review the activity of docetaxel after prior
abiraterone. To this end, we analyzed all retrospective reports in the literature describ-
ing the overall survival (OS) of mCRPC patients treated with docetaxel after previous
abiraterone. The mean OS observed was 12.7 mo, which suggested a significant decre-
ment compared with the 19.2 mo seen in the updated analysis of the TAX 327 study;
however, the data are quite similar to the OS of 13.6 mo (95% confidence interval, 12.1–
15.1 mo) described in a retrospective single-institution study of 357 men with mCRPC
treated with docetaxel with no prior abiraterone mostly in routine practice (86.3%).
Because the characteristics of patients recruited in phase 3 trials tend to differ from the
real-world setting, we deemed this data set a relevant comparison. Consequently,
despite the limitations of retrospective cross-study comparisons, the data suggest that
docetaxel retains activity when used as second-line therapy after abiraterone for mCRPC
patients.
Patient summary: We reviewed the activity of docetaxel after prior use of abiraterone
and considered the results in the light of the outcomes of docetaxel used as first-
line therapy for metastatic castration-resistant prostate cancer (mCRPC) patients in
routine practice. We noted that docetaxel retains reasonable activity and is a useful
agent for the treatment of mCRPC patients before or after abiraterone.
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E-mail address: edoardoFor >6 yr, docetaxel with prednisone was the only therapy
proven to prolong overall survival (OS) in patients with
metastatic castration-resistant prostate cancer (mCRPC) [1]
and became the standard of care; however, not all men were
considered fit for chemotherapy and thus were not treated
with docetaxel. Furthermore, in a retrospective single-
institution study of 357 men with mCRPC treated with
docetaxel from 2001 to 2011 mostly in routine practice
(86.3%), the median OS was 13.6 mo (95% confidencehttp://dx.doi.org/10.1016/j.eururo.2016.05.002
0302-2838/# 2016 European Association of Urology. Published by Elsevierinterval [CI], 12.1–15.1 mo) compared with 19.2 mo (95% CI,
17.5–21.3 mo) observed in the updated analysis of the TAX
327 study [2]. The authors concluded that survival of
patients with mCRPC treated with docetaxel in clinical
practice is shorter and is associated with more toxicity than
that of men included in trials [3].
The recent advent of two novel androgen receptor (AR)
targeted therapies—abiraterone acetate, a selective irre-
versible inhibitor of P-450c17, and enzalutamide, a potentB.V. All rights reserved.
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peutic landscape of mCRPC. Given their improved survival
benefit, lower adverse event profile, oral administration,
and consequently greater proportions of patients who are
candidates for these therapies, they became the more
common first-line treatment. Analyses of prescriptions
showed that in 2010, 91% of US men with mCRPC fit for
available therapy received docetaxel as first-line treatment,
whereas in 2013, this number had decreased to only 15%, as
67% of patients were treated with abiraterone as first-line
mCRPC therapy [4].
At this juncture, it was questioned whether the efficacy of
docetaxel was affected by prior abiraterone. To this end,
several retrospective reports identified by a literature search
(Appendix) investigated the clinical outcomes of mCRPC
patients treated with docetaxel after previous abiraterone
[5–9]. In aggregate, results showed that prostate-specific
antigen (PSA) decline 50% ranged from 13% to 48%, and OS
ranged from 12.4 to 14.4 mo (Table 1). Interestingly, some of
these papers noted no response to docetaxel in patients who
showed primary resistance to abiraterone [6,7]. This led to
speculation about the possibility of cross-resistance between
abiraterone and docetaxel. Conversely, a report by Schweizer
et al, who compared the efficacy of docetaxel in patients who
did (n = 24) or did not (n = 95) receive prior abiraterone,
described responses to docetaxel in the group of patients who
had no response to prior abiraterone [7]. These results were
also supported by a Canadian multicenter retrospective
study that retrospectively analyzed 86 patients treated with
docetaxel after failure of abiraterone. A PSA decline of 50%
was observed in 30 of 86 patients (35%; 95% CI, 26–45%), and
the median OS was 11.66 mo (95% CI, 9.45–13.88 mo);Table 1 – Patient characteristics and results










After abiraterone No No No
Patients, n 335 386 314
Age, yr, median 68 70 71
Gleason score, n (%)
6–7 141 (42) – 105 (43)
8–10 104 (31) – 142 (58)
PS, %
Poor 13 * 10  29 #
Median PSA, ng/mL 114 84 164
Sites of disease, n (%)
Bone 301 (90) 324 (84) 273 (87)
Lymph nodes – 93 (24) 159 (51)
Visceral 74 (22) 69 (18) 60 (19)
OS, mo
Median 19.2 17.5 13.6
95% CI 17.5–21.3 – 12.1–15.1
PSA decline 50%, %
Rate 45 50 45
95% CI 40–51 – 39–51
CI = confidence interval; OS = overall survival; PS = performance status; PSA = pro
* Karnofsky PS 70.
 SWOG PS 2.
# Eastern Cooperative Oncology Group PS 2.however, no statistically significant differences in PSA
response or OS were observed for patients with no PSA
decline, with <50% decline, and with 50% decline on
abiraterone [9].
The conflicting findings of these retrospective reports
highlight the need for prospective multicenter evaluations
of therapies rather than drawing conclusions from single-
institution reports based on end points of unclear signifi-
cance such as PSA decline. In this respect, a post hoc analysis
of COU-AA-302 revealed that 27% of 100 patients who had
docetaxel after abiraterone and at least one PSA measure-
ment on therapy had a confirmed decline of 50%
[10]. Nonetheless, there was consistency of the median
OS for all of these studies of men treated with docetaxel
after abiraterone, and the mean OS value was 12.7 mo. At
first look, these data would suggest a significant decrement
of activity of docetaxel used after abiraterone compared
with docetaxel used with no prior abiraterone, as reported
in the final survival analysis of TAX 327 (OS was 19.2 mo)
[2]. However, if compared with the OS achieved with first-
line docetaxel in routine practice [3], the OS of docetaxel
after abiraterone reported in similar institutional retro-
spective reviews appears similar (13.6 vs 12.7 mo). The
discrepancy between the results from clinical practice and
the OS from the phase 3 clinical trial setting is probably due
to the restrictiveness of the eligibility criteria. At baseline,
patients in TAX 327 had better prognostic features [1_TD$DIFF] than
those in the series by Templeton et al. [3] (Table 1): poor
performance score, 13% versus 29%; Gleason score 8–10,
31% versus 58%; and median PSA, 114 versus 164 ng/ml. As
such, it should be noted that the characteristics of the trial















Yes Yes Yes Yes
35 86 23 15
71 71 67 71
14 (40) 27 (31) 6 (26) 3 (20)
18 (51) 46 (53) 17 (74) 11 (73)
9 # 34 # – 7 #
232 184 260 67
33 (94) 81 (94) 21 (91) 12 (80)
10 (31) 46 (53) – 6 (40)
4 (11) 17 (20) 2 (9) 3 (8)
12.5 11.66 12.4 14.4
10.6–19.4 9.4–13.9 8.2–19.6 6.3–22.4
26 35 48 13
13–43 26–45 – –
state-specific antigen.
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prognostic nomograms [10_TD$DIFF] [11]. This holds particularly true for
prostate cancer patients who are often elderly, have
comorbidities, and may be more vulnerable to the adverse
events of any given therapy, particularly a cytotoxic one
such as docetaxel. Consequently, even though in phase
3 trials the OS benefit provides evidence of the clinical
activity of docetaxel, we cannot assume the general
population will have the same survival rates. The more
appropriate comparison might be the aggregate OS data
gathered from the studies on docetaxel as second-line
therapy after abiraterone beyond a clinical trial setting
(12.7 mo) versus the 13.6 mo reported by Templeton et al.
[3]. When considered in this light, it would appear that
docetaxel after abiraterone maintains a degree of activity
similar to that when given without prior abiraterone in
routine practice. Unfortunately, the only comparisons that
can be made are cross-study comparisons of PSA decline,
time to progression, and OS rates from registry data, as
randomized controlled trials are not available. Because
docetaxel after abiraterone is used at a later and potentially
more aggressive stage, one could postulate that it would be
less effective. Alternatively, it is known that non–AR-
dependent disease is sensitive to docetaxel in CRPC as well
as in lung, breast, and gastric cancer.
In conclusion, given the limitations of retrospective cross-
study comparisons, the totality of the data would suggest
that docetaxel used as second-line therapy after abiraterone
retains reasonable activity and is a useful agent for the
treatment of mCRPC patients, before or after abiraterone.
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The PubMed/Medline, Embase, LILACS, Cochrane Library,
and American Society of Clinical Oncology (ASCO) and
European Society of Medical Oncology (ESMO) abstracts
databases were searched for relevant articles using the
following terms: docetaxel after abiraterone, abiraterone
followed by docetaxel, docetaxel with prior abiraterone,
abiraterone before docetaxel, abiraterone and subsequent
docetaxel.
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